巨子 ICON - 財經股票資訊及專家分析
快訊
資訊
    虛擬市場
    搜尋 股票/指數/編號

    快訊

    資訊

    Nkarta

    NKTX
    17.770
    0.600
    3.27%
    最少15分鐘延遲,股票資訊由第三方資訊供應商提供
    ・Nkarta - 延遲價格・最後更新於 16/08 12:00
    最高位
    18.280
    最低位
    17.250
    開市價
    --
    前收市價
    18.370
    成交量(千)
    26.71
    成交額(百萬)
    4.15
    買入
    --
    賣出
    --
    每手股數
    --
    市值(百萬)
    864.63
    市盈率
    --
    息率
    --
    差價
    --
    52週高低
    37.100 - 7.550
    所有資料不保證絕對正確、完整、或實時,僅作為參考使用。投資涉及風險,過往業績並不代表將來表現,作任何投資決定或交易前,閣下應諮詢獨立專業意見。所有內容均不構成投資建議。

    企業資料

    公司名稱
    Nkarta
    證券代碼
    NKTX.US
    所屬板塊
    Biotechnology
    公司業務
    Nkarta Inc is a biopharmaceutical company developing engineered natural killer (NK) cells to fight cancer. The company is focused on leveraging the natural potent power of NK cells to identify and kill abnormal cells and recruit adaptive immune effectors to generate responses that are specific and durable. It is combining its NK expansion platform technology with proprietary cell engineering technologies to generate an abundant supply of NK cells, engineer enhanced NK cell recognition of tumor targets, and improve persistence for sustained activity in the body for the treatment of cancer. The company's operations are based in South San Francisco, California and it operates in one segment.
    發行量
    48404331
    公司總部
    6000 Shoreline Court, Suite 102
    公司網址
    https://www.nkartatx.com
    公司電話
    +1 415 582-4923

    Nkarta(NKTX.US)第四季度虧損擴大但強於預期 斯迪富降低其目標價

    格隆匯·
    Nkarta(NKTX.US)第四季度虧損擴大但強於預期 斯迪富降低其目標價

    關於

    Nkarta(NKTX.US)所屬的行業板塊為Biotechnology。
    Nkarta Inc is a biopharmaceutical company developing engineered natural killer (NK) cells to fight cancer. The company is focused on leveraging the natural potent power of NK cells to identify and kill abnormal cells and recruit adaptive immune effectors to generate responses that are specific and durable. It is combining its NK expansion platform technology with proprietary cell engineering technologies to generate an abundant supply of NK cells, engineer enhanced NK cell recognition of tumor targets, and improve persistence for sustained activity in the body for the treatment of cancer. The company's operations are based in South San Francisco, California and it operates in one segment.
    詳細公司背景可參考: https://www.nkartatx.com